Primary-source record
LeonaBio updated guidance that it remains on track to complete enrollment of the Phase 3 ELAINE-3 trial of lasofoxifene plus abemaciclib in 4Q 2026, with topline PFS data now expected in 2H 2027. The company continues to advance regulatory, manufacturing and commercial readiness activities in parallel.
EX-99.1 2 lona-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 LeonaBio Reports Third Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., November 16, 2026 – LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended September 30, 2026, and provided recent pipeline and business updates. “We continue to execute with focus and discipline as we advance ELAINE-3 and target completion of enrollment in the fourth quarter of 2026,” said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. “With enrollment nearing completion, we are entering a pivotal phase in the development of lasofoxifene. Our efforts extend beyond clinical execution as we advance regulatory, manufacturing and commercial readiness activities designed to support a potential launch and maximize the opportunity to bring this important therapy to patients as efficiently as possible.” “We believe lasofoxifene has the potential to redefine treatment for patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, a population that continues to face disease progression despite advances in care. T